Stoic VC
VC Fund
Sydney, Australia
Stoic VC is a VC fund in Sydney focused on Biotechnology and Medical. Investing at the frontier of research innovation.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 4%
- Fund size:
- $11M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Stoic VC invests in
Stages Stoic VC invests in
Countries Stoic VC invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $600k–$4.6M
- Series A
- $8.3M–$16M
- Venture - Series Unknown
- $2.2M–$24M
Investment Focus
Industry
- Biotechnology 7 (28%)
- Medical 4 (16%)
- Health Care 4 (16%)
- Software 3 (12%)
- Biopharma 3 (12%)
Stage
- Seed 9 (36%)
- Venture - Series Unknown 5 (20%)
- Series A 4 (16%)
- Series B 2 (8%)
- Funding Round 2 (8%)
Country
- Australia 16 (64%)
- United States 1 (4%)
- United Kingdom 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Fiona Zhuang
General Partner
|
General Partner | Total investments: 0 | Find email | |
Geoff Waring
Co-Founder & Managing Partner
|
Co-Founder & Managing Partner | Total investments: 0 | Find email | |
Guy Hedley
Co-Founder & General Partner
|
Co-Founder & General Partner | Total investments: 0 | Find email | |
Harikesh Pushpapathan
Portfolio Manager
|
Portfolio Manager | Total investments: 0 | Find email | |
|
Jade Bao
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $22.4M / Series B / Oct 22, 2025 | ||
| Kinoxis Therapeutics is an early stage biotechnology company based in Australia that is working to progress the development of a range of novel therapeutic compounds for the treatment of substance use disorders and other CNS conditions. The company has licensed these compounds from the University of Sydney, with the lead candidate demonstratingpotent anti-addictive and prosocial effects in a number of different animal models and is progressing through pre-clinical testing. | $9.5M / Series B / Aug 12, 2024 | ||
| Lenexa Medical is an Australian based MedTech company. | $1M / Seed / Feb 03, 2023 | ||
| BioScout utilises state-of-the-art technology to detect and prevent airborne diseases allowing for proactive disease management on farms worldwide! | $1.2M / Seed / Jun 20, 2022 | ||
| LM Plus is an operator of a technology company intended to develop unique liquid metal-based technology. | $600K / Seed / Aug 02, 2021 | ||
| Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $24.2M / Venture - Series Unknown / Jun 17, 2021 | ||
| Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $8.3M / Series A / Sep 28, 2020 | ||
| Wildlife Drones has developed the world’s most innovative animal radio-tracking system using drones so you can track your radio-tagged animals like never before. With over 25 years experience undertaking ecological and scientific animal research, they understand the immense frustration when trying to track the movements of highly mobile animals.Receiving clear signals from radio-tagged animals can be difficult to achieve and is often a very labour intensive and expensive process. The main issue is height. When using hand-held radio-tracking from the ground, you often have to get the antenna as high as possible in order to improve signal detection. This often means finding higher ground, or even hiring helicopters or planes to get the slightest “ping” of a distant radio-tag. Unfortunately, it also often results in losing track of the precious animals you have worked so very hard to tag in order to understand their movements. | Venture - Series Unknown / Dec 23, 2019 | ||
| OccuRx, a Melbourne-based biopharmaceutical company, was established in 2014 with venture funding from the Medical Research Commercialisation Fund, Brandon Capital Partners and Uniseed. The Company’s primary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis. | Series A / Nov 15, 2019 | ||
| Certa is an operational management platform that provides a fully integrated suite of products for third-party lifecycle management. The company's automated SaaS platform is used for business-to-business interactions, including on-boarding, due diligence, risk mitigation, and monitoring of third-party relationships. | $1.7M / Seed / Jun 04, 2019 | ||
| See all 25 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Stoic VC invest in?
Stoic VC invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Venture - Series Unknown stage. Most of the 25 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Stoic VC's check size?
Stoic VC typically joins rounds of $600k–$4.6M at Seed, $8.3M–$16M at Series A and $2.2M–$24M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Stoic VC participates in.
How do I contact Stoic VC?
Public channels for Stoic VC include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Stoic VC?
The team at Stoic VC includes Fiona Zhuang (General Partner), Geoff Waring (Co-Founder & Managing Partner) and Guy Hedley (Co-Founder & General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
